New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 21, 2013
08:54 EDTMNKDSummer Street 'much more optimistic' about MannKind approval
After speaking with a former FDA reviewer, Summer Street said it is "much more optimistic" that current trials of MannKind's inhalable insulin for treating type 1 and type 2 diabetes could lead to FDA approval. Summer Street said the consultant it spoke to sees an 85% chance that in the type 1 diabetes study Afrezza hits its endpoint. Shares of MannKind are up 13c to $6.83 in pre-market trading.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:47 EDTMNKDMannKind's Afrezza lags behind in inhaled insulin market, The Street reports
The number of prescriptions written for MannKind's (MNKD) Afrezza is lagging behind in the diabetes market, reports The Street. This comes five months after Sanofi (SNY) launched the product. Afrezza is also under-performing Exubera, the first inhaled insulin launched by Pfizer (PFE) nine years ago. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use